RSS Feed for Latest Medical Headlines on RxPG News

Medical Research Health Special Topics World

 
  Home
 
   Health
 Aging
 Asian Health
 Events
 Fitness
 Food & Nutrition
 Happiness
 Men's Health
 Mental Health
 Occupational Health
 Parenting
 Public Health
 Sleep Hygiene
 Women's Health
 
   Healthcare
 Africa
 Australia
 Canada Healthcare
 China Healthcare
 India Healthcare
 New Zealand
 South Africa
 UK
 USA
 World Healthcare
 
   Latest Research
 Aging
 Alternative Medicine
 Anaethesia
 Biochemistry
 Biotechnology
 Cancer
 Cardiology
 Clinical Trials
 Cytology
 Dental
 Dermatology
 Embryology
 Endocrinology
 ENT
 Environment
 Epidemiology
 Gastroenterology
 Genetics
 Gynaecology
 Haematology
 Immunology
 Infectious Diseases
 Medicine
 Metabolism
 Microbiology
 Musculoskeletal
 Nephrology
 Neurosciences
 Obstetrics
 Ophthalmology
 Orthopedics
 Paediatrics
 Pathology
 Pharmacology
  Adrenergics
  Analgesics
  Anti Cancer Drugs
  Anti-Clotting Drugs
  Anti-Inflammatory
  Antibiotics
  Anticholesterol
  Antihypertensives
  Antivirals
   Bavituximab
   Entecavir
  Fatty Acids
  Hypnotics
  Metals
  PPI
  Surfactants
  Varenicline
 Physiology
 Physiotherapy
 Psychiatry
 Radiology
 Rheumatology
 Sports Medicine
 Surgery
 Toxicology
 Urology
 
   Medical News
 Awards & Prizes
 Epidemics
 Launch
 Opinion
 Professionals
 
   Special Topics
 Ethics
 Euthanasia
 Evolution
 Feature
 Odd Medical News
 Climate
Search

Latest Research : Pharmacology : Antivirals
  Last Updated: Nov 2, 2013 - 11:52:55 AM

Latest Research : Pharmacology : Antivirals : Bavituximab
Phase Ib Trial Is Evaluating Bavituximab Administered With Common Chemotherapy Regimens
Peregrine Pharmaceuticals, Inc. (Nasdaq: PPHM), a clinical stage biopharmaceutical company developing targeted therapeutics for the treatment of cancer and hepatitis C virus (HCV) infection, today announced initiation of patient treatment in its Phase lb clinical trial to evaluate its lead anti-phospholipid immunotherapy agent bavituximab given in combination with common cancer chemotherapy agents. The trial is expected to enroll up to 12 patients at three clinical sites in India.
Nov 17, 2006 - 10:32:00 PM

Latest Research : Pharmacology : Antivirals : Bavituximab
Complete Inhibition of Viral Replication in H5N1 In Vivo Model by Bavituximab
Peregrine Pharmaceuticals, a biopharmaceutical company with a portfolio of innovative, clinical stage product candidates for the treatment of hepatitis C virus (HCV) infection and cancer, today announced that its lead anti-viral compound bavituximab (formerly Tarvacin) completely inhibited replication of a laboratory strain of the H5N1 virus, commonly known as avian flu, in fertilized chicken eggs, an in vivo model for influenza anti- viral activity. These preliminary findings will be reported today at the 106th general meeting of The American Society for Microbiology (ASM) in Orlando, Florida by Dr. Philip Thorpe, a member of the Peregrine Scientific Resource Board and professor of pharmacology at the University of Texas Southwestern Medical Center at Dallas. Bavituximab, a monoclonal antibody with unique anti-viral and anti-cancer properties, has already demonstrated good tolerability in a Phase l trial in patients with HCV infection.
May 25, 2006 - 1:09:00 PM

Latest Research : Pharmacology : Antivirals
FDA Gives Tentative Approval to Abacavir
The Food and Drug Administration (FDA) today announced the tentative approval of generic abacavir (a-BAK-a-veer) sulfate tablets manufactured by Aurobindo Pharma LTD. of Hyderabad, India. Abacavir sulfate tablets are the first generic version of the already approved Ziagen Tablets, an anti-HIV medication manufactured by GlaxoSmithKline. This product will now be available for consideration for purchase under the President's Emergency Plan for AIDS Relief.
May 20, 2006 - 3:01:00 AM

Latest Research : Pharmacology : Antivirals
Telbivudine emerging as a potent new treatment option for Hepatitis B
Novartis Pharma AG and Idenix Pharmaceuticals, Inc. announced today that the phase III GLOBE registration trial for telbivudine successfully reached its primary, composite efficacy endpoint of therapeutic response at one year in chronic hepatitis B patients.
Jul 29, 2005 - 10:25:00 PM

Latest Research : Pharmacology : Antivirals
New Saquinavir Formulation Simplifies Dosing Regimen for HIV Patients
Roche announced the European marketing approval for its new 500 mg formulation of Invirase (saquinavir mesylate), an effective and well tolerated protease inhibitor used in the treatment of HIV infection. The new 500 mg tablet will simplify the dosing regimen for patients by reducing the daily tablet count by more than half, from five tablets twice-daily to two tablets twice-daily.
May 30, 2005 - 8:48:00 PM

Latest Research : Pharmacology : Antivirals
CPG 10101 Shows Significant Antiviral Activity in Chronic Hepatitis C Patients
Coley Pharmaceutical Group, Inc today announced at the Digestive Disease Week conference that Actilon(TM) (CPG 10101) was relatively well tolerated and showed antiviral activity in the company's Phase Ib clinical study in chronic Hepatitis C patients.
May 23, 2005 - 11:21:00 AM

Latest Research : Pharmacology : Antivirals
Further Studies Needed for Tipranavir
Boehringer Ingelheim's Aptivus should be approved for treatment resistant HIV patients, but further studies are needed to guide use of the drug, FDA's Antiviral Drugs Advisory Committee recommended May 19.
May 20, 2005 - 8:27:00 AM

Latest Research : Pharmacology : Antivirals
Comparator Arm Suboptimal in Tipranavir Trial
Patient resistance to comparator protease inhibitors used in Boehringer Ingelheim's Aptivus (tipranavir) pivotal trials will likely be a central issue in the Antiviral Drugs Advisory Committee's review of the HIV agent.
May 19, 2005 - 8:48:00 AM

Latest Research : Pharmacology : Antivirals
Telbivudine Demonstrates Advantages Over Lamivudine in HBeAg-positive Chronic Hepatitis B
Idenix Pharmaceuticals, Inc. today announced the presentation of interim two-year results from an extended-treatment phase IIb clinical trial for telbivudine demonstrating continuing advantages compared to lamivudine across key efficacy endpoints through two years of treatment in HBeAg-positive chronic hepatitis B patients.
May 17, 2005 - 8:53:00 AM

Latest Research : Pharmacology : Antivirals
VX-950 : An Oral Hepatitis C virus Protease Inhibitor Shows Potent Antiviral Activity
Vertex Pharmaceuticals Incorporated (Nasdaq: VRTX) today announced interim results that indicate that the investigational oral hepatitis C virus (HCV) protease inhibitor VX-950 was well-tolerated and demonstrated potent antiviral activity in a Phase Ib clinical trial.
May 10, 2005 - 8:06:00 PM

Latest Research : Pharmacology : Antivirals : Entecavir
Baraclude™ (Entecavir) For Treatment Of Chronic Hepatitis B approved by FDA
Bristol-Myers Squibb Company (NYSE: BMY) announced today that the U.S. Food and Drug Administration (FDA) approved Baraclude™ (entecavir).
Mar 31, 2005 - 9:26:00 PM

<< prev next >>

 
Headlines
Health  
Gathering information about food is not top priority for individuals with high metabolisms
NIH renews funding for University of Maryland vaccine research
DHA-enriched formula in infancy linked to positive cognitive outcomes in childhood
New IOM report lays out plan to determine effectiveness of obesity prevention efforts
Vitamin D supplementation may delay precocious puberty in girls
Study: Pedometer program helps motivate participants to sit less, move more
Fish oil may stall effects of junk food on brain
Intake of low energy dense food better than skipping meals
Inaugural IOF Olof Johnell Science Award presented to Professor Harry Genant
Molecular hub links obesity, heart disease to high blood pressure
Healthcare  
Healthcare experts from UK and India meet at the UK Parliament to discuss ways to improve health care in India, UK
Flu pandemic infected one in five
Stigma preventing leprosy-cured from getting jobs
Measles, Mumps make a comeback in US
Melinda Gates calls on Akhilesh Yadav
'Movies, TV impact tobacco users more than newspapers'
Rockland to open three new hospitals in NCR
Spice Global enters healthcare business with hospital in Delhi
Delhi to expedite recruitment of doctors
India adds spice to US life, keeps it healthy
Latest Research  
How do consumers see a product when they hear music?
Drug activates virus against cancer
Bone loss associated with increased production of ROS
Sound preconditioning prevents ototoxic drug-induced hearing loss in mice
Crystal methamphetamine use by street youth increases risk of injecting drugs
Johns Hopkins-led study shows increased life expectancy among family caregivers
Moderate to severe psoriasis linked to chronic kidney disease, say experts
Licensing deal marks coming of age for University of Washington, University of Alabama-Birmingham
Simple blood or urine test to identify blinding disease
Physician job satisfaction driven by quality of patient care
Medical News  
NHRC issues notice to Kerala over infant deaths
Advanced breast cancer detecting machine comes to India
'Dispel myths about vitiligo'
NHRC summons Odisha chief secretary
Woman dies of swine flu in UP
Maharashtra, GE to modernise rural health care
Hypertension: India's silent killer
Need cautious effort to eradicate polio: Experts
Ayurveda experts develop online personalised health regimen
Soon a detailed study on 'diabesity': Doctors
Special Topics  
MPs express anguish at Delhi gang-rape, Shinde assures fast trial
Worrying rise in number of medical students in prostitution over last 10 years
Behold India's unfolding democratic revolution
Chinese woman cuts open her belly to save surgery cost
Improved Sense of Smell Produced Smarter Mammals
Two-year-old world's first to have extra DNA strand
172,155 kidney stones removed from one patient!
'Primodial Soup' theory for origin of life rejected in paper
Human species could have killed Neanderthal man
History, geography also seem to shape our genome

All rights reserved by RxPG
Contact Us